ANAPTYSBIO, INC

Rule 10b5-1 Trading Arrangements

On April 11, 2025, Daniel Faga, chief executive officer of the company, entered into a written plan for the potential sale of common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. No shares were sold under the plan and it was subsequently terminated on July 15, 2025.

On April 11, 2025, Dennis Mulroy, chief financial officer of the company, entered into a written plan for the potential sale of up to an aggregate 25,725 shares of common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is scheduled to terminate no later than December 31, 2025.

On April 11, 2025, Eric Loumeau, chief legal officer of the company, entered into a written plan for the potential sale of up to an aggregate 59,828 shares of common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is scheduled to terminate no later than May 20, 2026.

On April 14, 2025, Paul Lizzul, chief medical officer of the company, entered into a written plan for the potential sale of up to an aggregate 36,500 shares of common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is scheduled to terminate no later than April 14, 2026.

Other than as disclosed above, during the three months ended June 30, 2025, none of the company’s directors or officers adopted orterminated any “Rule 10b5-1 trading arrangements” or any “non-Rule 10b5-1 trading arrangements,” as each term is defined in Item 408 of Regulation S-K.